Your session is about to expire
← Back to Search
Favezelimab + Pembrolizumab for Hodgkin Lymphoma
Study Summary
This trial will compare a new combo drug to chemo for Hodgkin Lymphoma. It'll assess safety and efficacy for survival.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My Hodgkin lymphoma is confirmed and shows up on special scans.I am still recovering from a major surgery.I have or had lung inflammation that needed steroids.I have another cancer that is getting worse or was treated in the last 3 years.I have seizures that are not well controlled.I have a history of HIV.I have an active heart condition.I haven't had radiotherapy or needed steroids for side effects in the last 2 weeks.I have had a stem cell or organ transplant in the last 5 years.I have a history of hemophagocytic lymphohistiocytosis.My cancer has worsened despite treatment with specific immune therapy.My cancer has spread to my brain or spinal cord.I have an immune system disorder or am on long-term steroids or other drugs that weaken my immune system.I am currently being treated for an infection.I haven't had cancer treatment or experimental drugs in the last 4 weeks.I can provide a recent (less than 5 years old) tumor sample that hasn't been exposed to radiation.I have an autoimmune disease treated in the last 2 years, not including replacement therapy.My Hodgkin lymphoma has returned or didn't respond to treatment, and I've tried all known beneficial treatments.
- Group 1: Chemotherapy (Bendamustine or Gemcitabine)
- Group 2: Favezelimab/Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential risks and side effects can be associated with Favezelimab/Pembrolizumab use?
"Evidence suggests Favezelimab/Pembrolizumab is safe, so we rate it a 3 on our scale. This Phase 3 trial has yielded positive results regarding efficacy and safety thus far."
Is the enrollment window for this experiment still open?
"The current status of this clinical trial, as can be seen on the official website (clinicaltrials.gov), is that it is actively enrolling participants. This research was initiated on October 18th 2022 and last updated March 31st 2023."
Is the clinical trial for this project being conducted at multiple sites across America?
"Patients may receive this treatment from the University of Kentucky Chandler Medical Center in Lexington, Ohio; Cleveland Clinic-Taussig Cancer Center in Cleveland, Sao Paulo; Fundação Pio XII - Hospital de Câncer de Barretos in Barretos, Guangdong; and an additional 21 sites."
How many individuals are actively engaged in this medical experiment?
"The sponsor of this trial, Merck Sharp & Dohme LLC, seeks 360 qualified participants from two locations in the US and one location in Sao Paulo. These include University of Kentucky Chandler Medical Center (Site 2201) in Lexington, Ohio and Cleveland Clinic-Taussig Cancer Center ( Site 2203) located within Cleveland as well as a medical centre situated in Sao Paulo."
Share this study with friends
Copy Link
Messenger